GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Millendo Therapeutics Inc (NAS:MLND) » Definitions » Median PS Value

Millendo Therapeutics (Millendo Therapeutics) Median PS Value : $0.00 (As of Apr. 25, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Millendo Therapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Millendo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $0. Millendo Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2024-04-25), Millendo Therapeutics's share price is $1.06. Millendo Therapeutics's Median PS Value is $0.00. Therefore, Millendo Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Millendo Therapeutics's Median PS Value or its related term are showing as below:

MLND's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Millendo Therapeutics Median PS Value Historical Data

The historical data trend for Millendo Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Millendo Therapeutics Median PS Value Chart

Millendo Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Millendo Therapeutics Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Millendo Therapeutics's Median PS Value

For the Biotechnology subindustry, Millendo Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Millendo Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Millendo Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Millendo Therapeutics's Price-to-Median-PS-Value falls into.



Millendo Therapeutics Median PS Value Calculation

Millendo Therapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
Millendo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Millendo Therapeutics  (NAS:MLND) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Millendo Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=1.06/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Millendo Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Millendo Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Millendo Therapeutics (Millendo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
110 Miller Avenue, Suite 100, Ann Arbor, MI, USA, 48104
Millendo Therapeutics Inc is a biopharmaceutical company.
Executives
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Howe John P Md director C/O BB&T, P O BOX 1250, WINSTON SALEM NC 27102-1250
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Carole Nuechterlein director C/O AVEXIS, INC., 2275 HALF DAY ROAD, SUITE 160, BANNOCKBURN IL 60015
Geoffrey Nichol director MEDAREX, 707 STATE ROAD, PRINCETON NJ 08540
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Christophe Arbet-engels officer: Chief Medical Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Ryan Zeidan officer: Chief Development Officer C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100, ANN ARBOR MI 48104
Julia C. Owens director, officer: President and CEO C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Tamara L Joseph officer: General Counsel and Secretary 32 GARRISON STREET, APT 50-103, BOSTON MA 02116
Arcudi Iii Louis J officer: Chief Financial Officer C/O IDERA PHARMACEUTICALS 167 SYDNEY ST, CAMBRIDGE MA 02139
Randall W Whitcomb director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Jeffery M. Brinza officer: Sec., CAO and General Counsel C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Pharis Mohideen officer: Chief Medical Officer C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451